Active Ingredient History
Decitabine was first synthesized by Pliml and Sorm in the Institute of Organic Chemistry, Czechoslovak Academy of Sciences in 1964. Later, the drug was approved by FDA for the treatment of myelodysplastic syndromes in patients with cancer. Upon administration the decitabine is metabolized to the active phosphorylated metabolite which is incorporated into DNA and thus inhibits DNA methyltransferase (decitabine deplete DNMT1). NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Aged (Phase 2/Phase 3)
Allografts (Phase 3)
Anemia, Aplastic (Phase 2)
Anemia, Refractory (Phase 3)
Anemia, Sickle Cell (Phase 2)
Bone Marrow Cells (Phase 2)
Bone Marrow Diseases (Phase 1)
Breast Neoplasms (Phase 2)
Breast Neoplasms, Male (Phase 1)
Burkitt Lymphoma (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Castration (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 1/Phase 2)
Congenital Bone Marrow Failure Syndromes (Phase 2)
COVID-19 (Phase 2)
Decitabine (Phase 2)
Digestive System Neoplasms (Phase 1/Phase 2)
Drugs, Investigational (Phase 2)
Drug Therapy (Phase 2/Phase 3)
Esophageal Neoplasms (Phase 1/Phase 2)
Esophageal Squamous Cell Carcinoma (Phase 2)
Extranodal Extension (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fusion Proteins, bcr-abl (Phase 2)
GATA2 Deficiency (Phase 1)
Glioma (Phase 1/Phase 2)
Graft vs Host Disease (Phase 3)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 1)
Healthy Volunteers (Phase 1)
Hematologic Diseases (Phase 3)
Hematopoietic Stem Cell Transplantation (Phase 2/Phase 3)
HIV (Phase 1)
Hodgkin Disease (Phase 2/Phase 3)
Induction Chemotherapy (Phase 3)
Karyotype (Phase 2)
Leukemia (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 1)
Leukemia, Monocytic, Acute (Phase 3)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Accelerated Phase (Phase 2)
Leukemia, Myeloid, Acute (Phase 4)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Acute (Phase 3)
Leukemia, Myelomonocytic, Juvenile (Phase 1)
Leukemia, Promyelocytic, Acute (Phase 1)
Lung Neoplasms (Phase 2)
Lymphocytes (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Early Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Extranodal NK-T-Cell (Phase 2)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 4)
Lymphoma, Large-Cell, Immunoblastic (Phase 4)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1/Phase 2)
Lymphoma, T-Cell (Early Phase 1)
Lymphoma, T-Cell, Cutaneous (Phase 1)
Lymphoma, T-Cell, Peripheral (Phase 3)
Medulloblastoma (Phase 1/Phase 2)
Melanoma (Phase 1/Phase 2)
Mesothelioma (Phase 1)
Mesothelioma, Malignant (Phase 1/Phase 2)
Multiple Myeloma (Phase 1)
Mutation (Phase 3)
Myeloproliferative Disorders (Phase 3)
Nasopharyngeal Carcinoma (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 1/Phase 2)
Neoplasms ()
Neoplasms, Germ Cell and Embryonal (Phase 1)
Neuroblastoma (Phase 1)
Neuroectodermal Tumors, Primitive (Phase 1/Phase 2)
Neutropenia (Phase 2)
Ovarian Neoplasms (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 2)
Pharmacokinetics (Phase 3)
Plasmacytoma (Phase 2)
Polycythemia Vera (Phase 2)
Precancerous Conditions (Phase 1)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Preleukemia (Phase 1)
Primary Myelofibrosis (Phase 2)
Prostatic Neoplasms (Phase 1/Phase 2)
Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Phase 3)
Recurrence (Phase 3)
Sarcoma (Phase 1)
Small Cell Lung Carcinoma (Phase 1)
Thalassemia (Phase 2)
Thrombocythemia, Essential (Phase 2)
Thrombocytopenia (Phase 3)
Thyroid Neoplasms (Phase 2)
Tumor Suppressor Protein p53 (Phase 2/Phase 3)
Urinary Bladder Neoplasms (Phase 1)
Vascular Grafting (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
